Brokerages Anticipate Jaguar Health Inc (NASDAQ:JAGX) to Post ($5.61) EPS

Jaguar Health Inc (NASDAQ:JAGX) has earned a consensus broker rating score of 2.00 (Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and one has given a strong buy recommendation to the company. Jaguar Health’s rating score has declined by 100% in the last three months as a result of a number of analysts’ upgrades and downgrades.

Brokerages have set a 1 year consensus target price of $10.00 for the company and are predicting that the company will post ($5.61) EPS for the current quarter, according to Zacks. Zacks has also assigned Jaguar Health an industry rank of 78 out of 256 based on the ratings given to related companies.

Several analysts recently issued reports on JAGX shares. HC Wainwright set a $10.00 target price on Jaguar Health and gave the stock a “buy” rating in a report on Tuesday, July 2nd. Zacks Investment Research upgraded Booz Allen Hamilton from a “hold” rating to a “buy” rating and set a $71.00 target price on the stock in a report on Friday, June 28th. Finally, ValuEngine lowered Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd.

JAGX traded down $0.21 on Friday, hitting $3.20. 376,443 shares of the company were exchanged, compared to its average volume of 391,314. Jaguar Health has a 12 month low of $3.16 and a 12 month high of $175.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.18 and a current ratio of 0.30. The company has a fifty day moving average price of $3.85.

Jaguar Health (NASDAQ:JAGX) last released its earnings results on Tuesday, May 21st. The biotechnology company reported ($12.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($13.29) by $0.70. Jaguar Health had a negative return on equity of 372.84% and a negative net margin of 667.59%. The business had revenue of $1.59 million for the quarter, compared to analyst estimates of $2.20 million. On average, research analysts forecast that Jaguar Health will post -6.07 earnings per share for the current year.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.

Read More: Trading Ex-Dividend Strategy

Get a free copy of the Zacks research report on Jaguar Health (JAGX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with's FREE daily email newsletter.